Comparison of comorbid conditions between neovascular age-related macular degeneration patients and a control cohort in the medicare population

Gergana P. Zlateva, Jonathan C. Javitt, Sonali N. Shah, Zhiyuan Zhou, Jane G. Murphy

Research output: Contribution to journalArticle

Abstract

PURPOSE: To determine whether comorbidities are more prevalent among individuals with neovascular age-related macular degeneration (NV-AMD) than individuals without AMD. METHODS: This 2-year, retrospective, case-control study included Medicare beneficiaries (standard 5% analytic sample) continuously enrolled from January 1, 2003, to December 31, 2004, excluding those in managed care plans. The NV-AMD cohort included individuals ≥65 at baseline with a diagnosis of NV-AMD in 2003 and 2004. Age-, gender-, and race-matched controls were selected from those with no AMD. Comparisons were made for 13 general categories of non-eye-related diseases and 18 specific comorbidities based on ICD-9-CM codes. Two-year prevalence was calculated by condition and cohort; odds ratios and 99% confidence intervals were calculated (logistic regression). RESULTS: Analyses included 26,057 subjects and an equal number of controls. Nearly all subjects had at least one comorbidity, and >80% in each cohort had five or more comorbidities across general disease categories. Prevalence of 7/13 general disease categories exceeded 50% in both cohorts; rates for 12/13 categories were significantly higher in those with NV-AMD (P <0.001). Prevalence of 13/14 non-eye-related and 4/4 eye-related specific comorbidities was significantly higher among NV-AMD subjects (P <0.05). A more than 20% greater odds for NV-AMD subjects was noted for hypertension, hypercholesterolemia, emphysema, chronic obstructive pulmonary disease, atherosclerosis, arthritis, coronary heart disease, cataract, glaucoma, and myopia. CONCLUSION: Patients with NV-AMD are significantly more likely to have comorbidities, many of which could be life-threatening.

Original languageEnglish (US)
Pages (from-to)1292-1299
Number of pages8
JournalRetina
Volume27
Issue number9
DOIs
StatePublished - Nov 2007

Fingerprint

Macular Degeneration
Medicare
Comorbidity
Population
Myopia
Emphysema
Managed Care Programs
International Classification of Diseases
Hypercholesterolemia
Glaucoma
Cataract
Chronic Obstructive Pulmonary Disease
Arthritis
Coronary Disease
Case-Control Studies
Atherosclerosis
Logistic Models
Odds Ratio
Confidence Intervals
Hypertension

Keywords

  • Age-related macular degeneration
  • Case-control study
  • Comorbidity
  • Medicare

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Comparison of comorbid conditions between neovascular age-related macular degeneration patients and a control cohort in the medicare population. / Zlateva, Gergana P.; Javitt, Jonathan C.; Shah, Sonali N.; Zhou, Zhiyuan; Murphy, Jane G.

In: Retina, Vol. 27, No. 9, 11.2007, p. 1292-1299.

Research output: Contribution to journalArticle

Zlateva, Gergana P. ; Javitt, Jonathan C. ; Shah, Sonali N. ; Zhou, Zhiyuan ; Murphy, Jane G. / Comparison of comorbid conditions between neovascular age-related macular degeneration patients and a control cohort in the medicare population. In: Retina. 2007 ; Vol. 27, No. 9. pp. 1292-1299.
@article{89a1f18a4a604afca52ffd5ca5d35781,
title = "Comparison of comorbid conditions between neovascular age-related macular degeneration patients and a control cohort in the medicare population",
abstract = "PURPOSE: To determine whether comorbidities are more prevalent among individuals with neovascular age-related macular degeneration (NV-AMD) than individuals without AMD. METHODS: This 2-year, retrospective, case-control study included Medicare beneficiaries (standard 5{\%} analytic sample) continuously enrolled from January 1, 2003, to December 31, 2004, excluding those in managed care plans. The NV-AMD cohort included individuals ≥65 at baseline with a diagnosis of NV-AMD in 2003 and 2004. Age-, gender-, and race-matched controls were selected from those with no AMD. Comparisons were made for 13 general categories of non-eye-related diseases and 18 specific comorbidities based on ICD-9-CM codes. Two-year prevalence was calculated by condition and cohort; odds ratios and 99{\%} confidence intervals were calculated (logistic regression). RESULTS: Analyses included 26,057 subjects and an equal number of controls. Nearly all subjects had at least one comorbidity, and >80{\%} in each cohort had five or more comorbidities across general disease categories. Prevalence of 7/13 general disease categories exceeded 50{\%} in both cohorts; rates for 12/13 categories were significantly higher in those with NV-AMD (P <0.001). Prevalence of 13/14 non-eye-related and 4/4 eye-related specific comorbidities was significantly higher among NV-AMD subjects (P <0.05). A more than 20{\%} greater odds for NV-AMD subjects was noted for hypertension, hypercholesterolemia, emphysema, chronic obstructive pulmonary disease, atherosclerosis, arthritis, coronary heart disease, cataract, glaucoma, and myopia. CONCLUSION: Patients with NV-AMD are significantly more likely to have comorbidities, many of which could be life-threatening.",
keywords = "Age-related macular degeneration, Case-control study, Comorbidity, Medicare",
author = "Zlateva, {Gergana P.} and Javitt, {Jonathan C.} and Shah, {Sonali N.} and Zhiyuan Zhou and Murphy, {Jane G.}",
year = "2007",
month = "11",
doi = "10.1097/01.iae.0000300915.81866.b8",
language = "English (US)",
volume = "27",
pages = "1292--1299",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Comparison of comorbid conditions between neovascular age-related macular degeneration patients and a control cohort in the medicare population

AU - Zlateva, Gergana P.

AU - Javitt, Jonathan C.

AU - Shah, Sonali N.

AU - Zhou, Zhiyuan

AU - Murphy, Jane G.

PY - 2007/11

Y1 - 2007/11

N2 - PURPOSE: To determine whether comorbidities are more prevalent among individuals with neovascular age-related macular degeneration (NV-AMD) than individuals without AMD. METHODS: This 2-year, retrospective, case-control study included Medicare beneficiaries (standard 5% analytic sample) continuously enrolled from January 1, 2003, to December 31, 2004, excluding those in managed care plans. The NV-AMD cohort included individuals ≥65 at baseline with a diagnosis of NV-AMD in 2003 and 2004. Age-, gender-, and race-matched controls were selected from those with no AMD. Comparisons were made for 13 general categories of non-eye-related diseases and 18 specific comorbidities based on ICD-9-CM codes. Two-year prevalence was calculated by condition and cohort; odds ratios and 99% confidence intervals were calculated (logistic regression). RESULTS: Analyses included 26,057 subjects and an equal number of controls. Nearly all subjects had at least one comorbidity, and >80% in each cohort had five or more comorbidities across general disease categories. Prevalence of 7/13 general disease categories exceeded 50% in both cohorts; rates for 12/13 categories were significantly higher in those with NV-AMD (P <0.001). Prevalence of 13/14 non-eye-related and 4/4 eye-related specific comorbidities was significantly higher among NV-AMD subjects (P <0.05). A more than 20% greater odds for NV-AMD subjects was noted for hypertension, hypercholesterolemia, emphysema, chronic obstructive pulmonary disease, atherosclerosis, arthritis, coronary heart disease, cataract, glaucoma, and myopia. CONCLUSION: Patients with NV-AMD are significantly more likely to have comorbidities, many of which could be life-threatening.

AB - PURPOSE: To determine whether comorbidities are more prevalent among individuals with neovascular age-related macular degeneration (NV-AMD) than individuals without AMD. METHODS: This 2-year, retrospective, case-control study included Medicare beneficiaries (standard 5% analytic sample) continuously enrolled from January 1, 2003, to December 31, 2004, excluding those in managed care plans. The NV-AMD cohort included individuals ≥65 at baseline with a diagnosis of NV-AMD in 2003 and 2004. Age-, gender-, and race-matched controls were selected from those with no AMD. Comparisons were made for 13 general categories of non-eye-related diseases and 18 specific comorbidities based on ICD-9-CM codes. Two-year prevalence was calculated by condition and cohort; odds ratios and 99% confidence intervals were calculated (logistic regression). RESULTS: Analyses included 26,057 subjects and an equal number of controls. Nearly all subjects had at least one comorbidity, and >80% in each cohort had five or more comorbidities across general disease categories. Prevalence of 7/13 general disease categories exceeded 50% in both cohorts; rates for 12/13 categories were significantly higher in those with NV-AMD (P <0.001). Prevalence of 13/14 non-eye-related and 4/4 eye-related specific comorbidities was significantly higher among NV-AMD subjects (P <0.05). A more than 20% greater odds for NV-AMD subjects was noted for hypertension, hypercholesterolemia, emphysema, chronic obstructive pulmonary disease, atherosclerosis, arthritis, coronary heart disease, cataract, glaucoma, and myopia. CONCLUSION: Patients with NV-AMD are significantly more likely to have comorbidities, many of which could be life-threatening.

KW - Age-related macular degeneration

KW - Case-control study

KW - Comorbidity

KW - Medicare

UR - http://www.scopus.com/inward/record.url?scp=36749003289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749003289&partnerID=8YFLogxK

U2 - 10.1097/01.iae.0000300915.81866.b8

DO - 10.1097/01.iae.0000300915.81866.b8

M3 - Article

VL - 27

SP - 1292

EP - 1299

JO - Retina

JF - Retina

SN - 0275-004X

IS - 9

ER -